<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02657681</url>
  </required_header>
  <id_info>
    <org_study_id>MJFOX-9205</org_study_id>
    <secondary_id>9205</secondary_id>
    <nct_id>NCT02657681</nct_id>
  </id_info>
  <brief_title>Prevention of Levodopa-induced Dyskinesias by Transcranial Static Magnetic Field Stimulation (tSMS)</brief_title>
  <official_title>Prevention of Levodopa-induced Dyskinesias by Transcranial Static Magnetic Field Stimulation (tSMS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación de investigación HM</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Michael J. Fox Foundation for Parkinson's Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Nacional de Parapléjicos de Toledo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital San Carlos, Madrid</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación de investigación HM</source>
  <brief_summary>
    <textblock>
      This is a randomized sham-controlled double-blind study to test the hypothesis that
      transcranial static magnetic field stimulation (tSMS) of the motor cortex improves
      levodopa-induced dyskinesias in patients with Parkinson's disease. Half of the patients will
      receive real tSMS treatment, the other half will receive sham treatment (placebo).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline of the maximal dyskinesia severity within 90min after levodopa intake, as measured by objective evaluation with the Unified Dyskinesia Rating Scale (UDysRS) one day after the end of treatment.</measure>
    <time_frame>One day after the end of treatment compared to baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of the maximal dyskinesia severity within 90min after levodopa intake, as measured by objective evaluation with the Unified Dyskinesia Rating Scale (UDysRS) one week after the end of treatment.</measure>
    <time_frame>One week after the end of treatment compared to baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyskinesia severity evaluated for each body segment</measure>
    <time_frame>Baseline, one day and one week after the end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective evaluation of the treatment, as measured by the patient global impression of change (PGIC)</measure>
    <time_frame>One day and one week after the end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in motor symptoms, as measured by the MDS-UDPRS III scale</measure>
    <time_frame>Baseline, one day and one week after the end of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Dyskinesia, Medication-Induced</condition>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>tSMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 min of tSMS, one session per day, for 9 days over 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sham</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>30 min of sham, one session per day, for 9 days over 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>tSMS</intervention_name>
    <description>Transcranial static magnetic field stimulation (tSMS) is a non-invasive brain stimulation (NIBS) technique that decreases cortical excitability. Static magnetic fields suitable for tSMS are obtained with commercially available neodymium magnets. We will use a cylindrical neodymium magnet of 45 mm diameter and 30 mm of thickness, with a weight of 360 g (MAG45r; Neurek SL, Toledo, Spain), which will be applied with south polarity to the motor cortex, over the representational field of hand area contralateral to the more affected side of the body.</description>
    <arm_group_label>tSMS</arm_group_label>
    <other_name>MAGmv1.0 with MAG45r, Neurek S.L. (Toledo, Spain)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>sham</intervention_name>
    <description>A non-magnetic metal cylinder, with the same size, weight and appearance of the magnet, will be used for sham stimulation (MAG45s; Neurek SL, Toledo, Spain).</description>
    <arm_group_label>sham</arm_group_label>
    <other_name>MAGmv1.0 with MAG45s, Neurek S.L. (Toledo, Spain)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  advanced idiopathic Parkinson's disease (Brain Bank criteria)

          -  optimal clinical response to dopaminergic medication (&gt;30% UPDRS-III improvement)

          -  presence of clinically relevant levodopa-induced peak-dose dyskinesias in at least one
             upper limb

        Exclusion Criteria:

          -  MRI-incompatible metal objects in the body (e.g. cardiac pacemakers)

          -  other main neuropsychiatric co-morbidity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guglielmo Foffani, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CINAC, Hospital Universitario HM Puerta del Sur</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guglielmo Foffani, PhD</last_name>
    <email>guglielmo.foffani@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CINAC, Hospital Universitario Puerta del Sur</name>
      <address>
        <city>Móstoles</city>
        <state>Madrid</state>
        <zip>28938</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guglielmo Foffani, PhD</last_name>
      <email>guglielmo.foffani@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2016</study_first_submitted>
  <study_first_submitted_qc>January 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2016</study_first_posted>
  <last_update_submitted>August 8, 2016</last_update_submitted>
  <last_update_submitted_qc>August 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundación de investigación HM</investigator_affiliation>
    <investigator_full_name>Guglielmo Foffani</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dyskinesias</mesh_term>
    <mesh_term>Dyskinesia, Drug-Induced</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

